These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Gatifloxacin-1,2,3-triazole-isatin hybrids and their antimycobacterial activities.
    Author: Ding Z, Hou P, Liu B.
    Journal: Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900135. PubMed ID: 31441087.
    Abstract:
    A series of gatifloxacin-1,2,3-triazole-isatin hybrids 8a-l were designed, synthesized, and screened for their in vitro antimycobacterial activity as well as cytotoxicity toward Chinese Hamster Ovary (CHO) cells. The synthesized hybrids showed considerable activity against MTB H37 Rv and two MDR-MTB strains with minimal inhibitory concentration (MIC) of 0.25-8 μg/ml, and the hybrid 8a (MICMTB H37Rv : 0.25 μg/ml and MICMDR-MTB : 0.5 and 1 μg/ml) was found to be most active against the tested strains, which was not inferior to the parent gatifloxacin (MIC: 0.5, 0.25, and 0.5 μg/ml) against all three tested strains, and was ≥128-fold more active than isoniazid (MIC: ≥64 μg/ml) and rifampicin (MIC: >128 μg/ml) against the two MDR-MTB strains. Moreover, hybrid 8a (CC50 : 8.0 μg/ml) also displayed acceptable cytotoxicity toward CHO cells, and the selectivity index was 32. The structure-activity relationship and structure-cytotoxicity relationship were also enriched.
    [Abstract] [Full Text] [Related] [New Search]